• 1
    Wimo A., Prince M., Alzheimer’s Disease International (ADI) (2010) World Alzheimer Report 2010: the global economic impact of dementia.
  • 2
    Hardy J., Selkoe D.J. (2002) The amyloid hypothesis of Alzheimer’s disease: progress and problems on the road to therapeutics. Science;297:353356.
  • 3
    Vassar R., Bennett B.D., Babu-Khan S., Kahn S., Mendiaz E.A., Denis P., Teplow D.B. et al. (1999) Beta-secretase cleavage of Alzheimer’s amyloid precursor protein by the transmembrane aspartic protease BACE. Science;286:735741.
  • 4
    Younkin S.G. (1998) The role of A beta 42 in Alzheimer’s disease. J Physiol (Paris);92:289292.
  • 5
    Beher D., Graham S.L. (2005) Protease inhibitors as potential disease modifying therapeutics for Alzheimer’s disease. Expert Opin Invest Drugs;14:13851409.
  • 6
    Citron M. (2010) Alzheimer’s disease: strategies for disease modification. Nature Rev;9:387398.
  • 7
    Farzan M., Schnitzler C.E., Vasilieva N., Leung D., Choe H. (2000) BACE2, a beta-secretase homolog, cleaves at the beta site and within the amyloid-beta region of the amyloid-beta precursor protein. Proc Natl Acad Sci U S A;97:97129717.
  • 8
    Saunders A.J., Kim T.-W., Tanzi R.E. (1999) BACE maps to chromosome 11 and a BACE homolog, BACE2, reside in the obligate Down syndrome region of chromosome 21. Science;286:1255.
  • 9
    Stachel S.J., Coburn C.A., Steele T.G., Jones K.G., Loutzenhiser E.F., Gregro A.R., Rajapakse H.A. et al. (2004) Structure-based design of potent and selective cell-permeable inhibitors of human β-secretase (BACE1). J Med Chem;47:64476450.
  • 10
    Charrier N., Clarke B., Cutler L., Demont E., Dingwall C., Dunsdon R., East P. et al. (2008) Second generation of hydroxyethylamine BACE1 inhibitors: optimizing potency and oral bioavailability. J Med Chem;51:33133317.
  • 11
    Hom R.K., Gailunas A.F., Mamo S., Fang L.Y., Tung J.S., Walker D.E., Davis D., Thorsett E.D., Jewett N.E., Moon J.B., John V. (2004) Design and synthesis of hydroxyethylene-based peptidomimetic inhibitors of human β-secretase. J Med Chem;47:158164.
  • 12
    Hom R.K., Fang L.Y., Mamo S., Tung J.S., Guinn A.C., Walker D.E., Davis D.L., Gailunas A.F., Thorsett E.D., Sinha S., Knops J.E., Jewett N.E., Anderson J.P., John V. (2003) Design and synthesis of statine-based cell-permeable peptidomimetic inhibitors of human β-secretase. J Med Chem;46:17991802.
  • 13
    Bäck M., Nhylén J., Kvarnström I., Apelgren S., Borkakoti N., Jansson K., Lindberg J., Nyström S., Hallberg A., Rosenquist A., Samuelsson B. (2008) Design, synthesis and SAR of potent statine-based BACE1 inhibitors: exploration of P1 phenoxy and benzyloxyresidues. Bioorg Med Chem;16:94719486.
  • 14
    Silvestri R.I.P., Fondazione C.B. (2009) Boom in the development of non-peptidic beta-secretase (BACE1) inhibitors for the treatment of Alzheimer’s disease. Med Res Rev;29:295338.
  • 15
    Huang W.H., Sheng R., Hu Y.Z. (2009) Progress in the development of nonpeptidomimetic BACE 1 inhibitors for Alzheimer’s disease. Curr Med Chem;16:18061820.
  • 16
    Xu W., Chen G., Zhu W., Zuo Z. (2010) Identification of a sub-micromolar, non-peptide inhibitor of β-secretase with low neural cytotoxicity through in silico screening. Bioorg Med Chem Lett;20:57635766.
  • 17
    Gianpaolo C., Andrea S., Francesca M., Vincenza A., Maria L.B., Marinella R., Maurizio R., Paolo C., Andrea C. (2011) Sequential virtual screening approach to the identification of small organic molecules as potential BACE-1 inhibitors. Chem Biol Drug Des;77:268271.
  • 18
    Vijayan R.S.K., Prabu M., Mascarenhas N.M., Ghoshal N. (2009) Hybrid structure-based virtual screening protocol for the identification of novel BACE1 inhibitors. J Chem Inf Model;46:647657.
  • 19
    Al-Nadaf A., Abu Sheikha G., Taha M.O. (2010) Elaborate ligand-based pharmacophore exploration and QSAR analysis guide the synthesis of novel pyridinium-based potent β-secretase inhibitory leads. Bioorg Med Chem;18:30883115.
  • 20
    Gao H.-F., Niu Y., Xu F.-R., Liang L., Zhou B., Li Y.-J., Wang C., Liu P., Xu P. (2012) Design and synthesis of benzimidamides as potential BACE1 inhibitors. J Chin Pharm Sci;21:124131.
  • 21
    Verdonk M.L., Cole J.C., Hartshorn M.J., Murray C.W., Taylor R.D. (2003) Improved protein–ligand docking using GOLD. Proteins;52:609623.
  • 22
    Murray C.W., Callaghan O., Chessari G., Cleasby A., Congreve M., Frederickson M., Hartshorn M.J., McMenamin R., Patel S., Wallis N. (2007) Application of fragment screening by X-ray crystallography to beta-secretase. J Med Chem;50:11161123.
  • 23
    Egan W.J., Lauri G. (2002) Prediction of intestinal permeability. Adv Drug Del Rev;54:273289.